secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001439222-23-000138
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q3: PYRUKYND rev $7.4M; first patient dosed in Phase 3 sickle cell; net loss $91.3M
--------------------------------------------------------------------------------

- PYRUKYND net revenue $7.4M in Q3 2023 (+10% QoQ); 100 patients on therapy, 160 completed enrollment forms.
- First patient dosed in Phase 3 portion of RISE UP pivotal study of mitapivat in sickle cell disease.
- Completed enrollment in Phase 3 ACTIVATE-kidsT; >50% enrolled in Phase 3 ACTIVATE-kids for pediatric PK deficiency.
- Net loss $91.3M in Q3 2023 vs $81.7M in Q3 2022; cash $872.4M as of Sep 30, 2023, funding into 2026.
- Topline data for AG-946 in LR-MDS expected by year-end 2023; Phase 3 thalassemia data in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922223000138/0001439222-23-000138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922223000138/agio-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001439222-23-000138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer